1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.
  2. Dear Guest, we realise advertising is annoying, it is however necessary to help us be a sustainable resource for all, if you want to go advert free then please use the following link to subscribe for £5 a month: Click here
    Dismiss Notice

Woodford sold his investment in January 2015.

Discussion in 'General Share Chat' started by Steamy, Apr 26, 2015.

  1. Inspiration

    Inspiration Moderator Moderator

    One FTSE 100 company that he has exited entirely is medical firm Smith & Nephew, a £10 billion market cap constituent of the FTSE 100.

    Woodford commented that the company has been subject to bid speculation, and while he acknowledges that a bid for the company might lead to ‘considerable’ appreciation in the share price, the shares are already ‘near their all-time highs, so we feel that there are better opportunities elsewhere’.
  2. Steamy

    Steamy Co-Founder of BlueShare Staff Member Moderator

    He is rarely wrong, he sold TESCO to Buffet.
    Inspiration likes this.
  3. Mongoose82

    Mongoose82 A Legendary Member

    "Smith & Nephew’s Q1 16 results (trading update) came in marginally below analysts’ expectation (sales of $1.14bn vs. consensus estimate of $1.17bn). The revenue growth of 3% was a function of underlying growth of 4%, acquisition benefits of 2% and currency headwinds of 3%. Franchise-wise, the robust performance of sports medicine, knee/hip implants and advanced wound devices was negated to some extent by the underperformance of trauma & extremities and advanced wound bioactives. Management has maintained its FY 16 outlook of good underlying revenue growth (not quantified). The forex situation has slightly improved and management now sees a negative impact of 0-1% (from an earlier 2-3%) on full-year revenue."

    AlphaValue broker note out this morning: https://www.research-tree.com/company/GB0009223206
    Inspiration likes this.

Share This Page